• Special Issue Topic

    Biosimilars: State of the Art in the Treatment of Rheumatic Diseases

    Submission Deadline: July 01, 2024

    Guest Editor

    Prof. Valderilio Feijó Azevedo E-Mail

    Federal University of Paraná, Brazil

    Research Keywords: Spondyloarthritis, gout, biopharmaceuticals, biosimilars, gut microbioma, psoriatic arthritis, pharmacoeconomics


    About the Special Issue

    Widespread use of biological medicines has transformed outcomes for many patients with inflammatory conditions such as autoimmune rheumatic disorders (ARDs). These therapies come at a price, however, and as their patents expire, a new class of products, very regulated copies named biosimilars are entering the market. Biosimilars are more affordable for healthcare organisations and enable greater patient access to treatment. Biosimilars are subject to a robust regulatory framework to gain approval worldwide. These products have shown biosimilarity in terms of structure, biological activity and therapeutic equivalence in efficacy, safety, and immunogenicity profile. Since the approval of the first Mab Biosimilar used to treat Rheumatic diseases in 2013, many other biosimilars are available as safe and cost reduced options to treat ARDs. A number of real-world scenarios, of a medical and non-medical nature, may lead to cross-switching between biosimilars of the same reference product. This special issue intend to discuss and point out new challenges for biosimilars in rheumatology.

    Keywords: Biosimilars, biologic medicines, biopharmaceuticals, reference products, rheumatic diseases

    Call for Papers

    Published Articles

    Open Access
    Perspective
    Selecting the best-value biosimilar in emerging countries
    The aim of biosimilars is to alleviate the financial burden of biological medicinal products. A most relevant challenge for emerging countries is how to select the best option available. In most cas [...] Read more.
    Gilberto Castañeda-Hernández
    Published: September 14, 2024 Explor Musculoskeletal Dis. 2024;2:423–430
    DOI: https://doi.org/10.37349/emd.2024.00067
    View:373
    Download:15
    Times Cited: 0
    Open Access
    Original Article
    Successful implementation of interchange of biologic medications in chronic arthritis after information of costs to prescribers
    Aim: To evaluate the impact of prescription, cost, and switching policy on the rate of switching from reference products to biosimilars. Methods: Analysis of an administrative database for  [...] Read more.
    Fernando Perez-Ruiz ... Amaya de Basagoiti-Gorordo
    Published: September 10, 2024 Explor Musculoskeletal Dis. 2024;2:384–390
    DOI: https://doi.org/10.37349/emd.2024.00064
    View:314
    Download:17
    Times Cited: 0